Teh Wei Pin, Zhu He, Marto Jarrod A, Buhrlage Sara J
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.
Mol Cell. 2022 Apr 21;82(8):1411-1413. doi: 10.1016/j.molcel.2022.03.039.
Henning et al. (2022) report development of a novel class of agents, bivalent deubiquitinase (DUB)-targeting chimeras (DUBTACs), that can selectively stabilize protein targets. These findings encourage further pursuit of targeted protein stabilization as a new paradigm in chemical biology and drug discovery.
亨宁等人（2022年）报告了一类新型药物的研发情况，即双价去泛素化酶（DUB）靶向嵌合体（DUBTACs），这类药物能够选择性地稳定蛋白质靶点。这些发现促使人们进一步探索将靶向蛋白质稳定化作为化学生物学和药物发现中的一种新范式。
